Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore called induced pluripotent stem...

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore called induced pluripotent stem...

EPS and iPS Cells in Disease Research

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...

Stem Cell Culture

Stem Cell Culture

Stem cell research aims to find ways to use stem cells to regenerate and repair cellular damage. Over time, most adult cells undergo the wear and tear of aging and lose their ability to divide and repair themselves. Stem cells do not display a particular morphology or function. Adult stem cells, which exist as a small subset of cells in most tissues, keep dividing and can differentiate into a number of specialized cells generally formed by that tissue. These cells enable the body to renew and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Serum Circulating Interleukin-8 DNA Levels Are Elevated in Patients With Palmoplantar Pustulosis.

The Journal of dermatology·2026

Same author

Bullous pemphigoid and Graves' disease developing during prolonged remission of pemphigus vulgaris.

European journal of dermatology : EJD·2026

Same author

Blockade for CD276-mediated suppression of tumor-specific cytotoxic T lymphocytes may contribute to achieving durable responses with immune checkpoint inhibitors.

The Journal of investigative dermatology·2026

Same author

Clinical utility of comprehensive genomic profiling in 175 Japanese patients with advanced skin malignancies refractory to standard therapies.

JAAD international·2026

Same author

Case of generalized morphea complicated with systemic sclerosis.

Dermatology reports·2026

Same author

Cutaneous Phaeohyphomycosis Caused by Exophiala jeanselmei.

Medical mycology journal·2026

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Pluripotent stem cell-derived dendritic cells for immunotherapy.

Satoru Senju¹, Yusuke Matsunaga, Satoshi Fukushima

¹The Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. senjusat@gpo.kumamoto-u.ac.jp

Frontiers in Bioscience (Elite Edition)

|June 3, 2010

Summary

This summary is machine-generated.

Dendritic cells (DCs) show promise in immunotherapy. Generating DCs from embryonic stem (ES) cells or induced pluripotent stem (iPS) cells overcomes limitations of current patient-derived cell therapies.

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Related Experiment Videos

Last Updated: Jun 12, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Area of Science:

Immunology
Stem Cell Biology
Cancer Therapy

Background:

Dendritic cells (DCs) are crucial for anti-cancer immunotherapy and managing immune responses in autoimmune diseases and transplantation.
Current clinical DC generation relies on patient monocytes, facing limitations in cell number and donor variability.
This poses a significant obstacle for widespread DC-based therapies.

Purpose of the Study:

To review the generation, characterization, and genetic modification of DCs derived from embryonic stem (ES) cells and induced pluripotent stem (iPS) cells.
To highlight the potential of ES and iPS cells as an alternative cell source for DC therapy.
To address the limitations of current monocyte-derived DC production.

Main Methods:

Review of existing literature on generating DCs from ES and iPS cells.
Analysis of methods for characterizing these novel DC populations.
Examination of techniques for genetic modification of ES/iPS-derived DCs.

Main Results:

ES and iPS cells offer a pluripotent and expandable cell source for DC generation.
Methods for generating and characterizing these DCs have been successfully developed by several research groups.
Genetic modification of these DCs is feasible, expanding therapeutic potential.

Conclusions:

ES and iPS cell-derived DCs represent a promising solution to the cell number limitations in current DC therapy.
These novel DC sources hold significant potential for advancing anti-cancer immunotherapy, autoimmune disease treatment, and transplantation medicine.
Further research and clinical application of ES/iPS-derived DCs are warranted.